EZH2 and cancer: We and others previously reported that PRC2 activity compensates to reinforce gene silencing following DNMT inhibition to maintain gene silencing in cancer, and this can be overcome through the use of inhibitors that selectively target EZH2, the primary catalytic subunit of PRC2 (15).